Y-mAbs Therapeutics

Executive Summary

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based treatments for cancer, with a focus on challenging pediatric and adult oncology indications. Its lead product, DANYELZA (naxitamab-gqgk), is approved in the U.S. for the treatment of high-risk neuroblastoma in pediatric patients. The company's proprietary SADA (Self-Assembling and DisAssembling) technology platform enables targeted delivery of radioisotopes to tumors, potentially improving efficacy and safety. Y-mAbs continues to invest in expanding DANYELZA's label and advancing its pipeline of novel therapies, including in combination with checkpoint inhibitors and other modalities. The company is also exploring the use of its SADA platform in other solid tumors, aiming to address significant unmet medical needs. With a strong commercial foundation and a robust pipeline, Y-mAbs is positioned for growth in the targeted cancer therapy space.

Upcoming Catalysts (preview)

• Q4 2026DANYELZA label expansion in newly diagnosed high-risk neuroblastoma60% success
• Q1 2027Top-line data from Phase 2 trial of naxitamab in combination with chemotherapy in relapsed/refractory osteosarcoma40% success
• Q3 2026Update on SADA platform proof-of-concept data in solid tumors50% success